Table VI.
Histopathology-histomorphometry analysis of the abdominal fat pads, uterus and liver in sham-operated or OVX ddY mice.
| Control | PCS | |||||
|---|---|---|---|---|---|---|
| Variable | Sham | OVX | Estradiol | 1 ml/kg | 2 ml/kg | 4 ml/kg |
| Abdominal fat pads | ||||||
| Total Th (mm) | 1.47±0.56 | 6.33±0.94b | 2.82±0.29b,e | 4.94±0.64b,e | 3.75±0.72b,e | 3.75±1.38b,e |
| Adipocyte DM (µm) | 36.09±10.80 | 133.37±20.97a | 66.05±16.12a,d | 98.94±15.53a,d | 75.16±15.70a,d | 72.71±22.41a,d |
| Uterus | ||||||
| Total Th (µm) | 2271.81±664.94 | 542.19±123.09b | 1609.39±364.98c,e | 757.88±89.21b,e | 908.06±83.37b,e | 910.73±155.32b,e |
| Epi Th (µm) | 35.64±6.06 | 7.54±1.45b | 21.39±4.32b,e | 13.22±2.94b,e | 17.81±4.46b,e | 17.97±4.87b,e |
| Mucosa Th (µm) | 991.09±243.96 | 194.15±52.74b | 627.08±163.07b,e | 306.49±59.11b,e | 424.09±91.22b,e | 426.09±101.39b,e |
| UG percentage (%) | 55.25±11.50 | 12.29±3.27b | 36.70±4.67b,e | 22.41±4.06b,e | 30.66±5.61b,e | 30.83±8.35b,e |
| Liver | ||||||
| FC region (%) | 13.06±3.18 | 79.55±6.78a | 42.53±8.11a,d | 64.28±11.93a,d | 49.28±13.38a,d | 47.81±13.06a,d |
| Hepatocyte DM (µm) | 10.43±4.21 | 32.71±4.47a | 18.09±3.84a,d | 24.77±2.11a,d | 21.51±2.18a,d | 21.49±5.23a,d |
Values are expressed mean ± standard deviation (n=8).
P<0.01 vs. sham control, determined by LSD test
P<0.01
P<0.05 vs. sham control, determined by MW test
P<0.01 vs. OVX control, determined by LSD test
P<0.01 vs. OVX control, determined by MW test. Three different dosages of PCS were orally administered, and 17β-estradiol was subcutaneously treated at a dose level of 0.03 µg/head on the dorsal back skins, once a day for 84 days from 28 days after OVX surgery. OVX, bilateral ovariectomy; PCS, pomegranate concentrated solution; Th, thickness; DM, diameter; Epi, epithelium; UG, uterine gland; FC, fatty change; LSD, least significant difference; MW, Mann-Whitney U.